Optimi Health (TSE:OPTI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Optimi Health has partnered with Psyence Biomed to supply GMP-certified psilocybin for clinical trials aimed at addressing unmet mental health needs in palliative care. This collaboration not only supports Psyence Biomed’s current Phase IIb trial but also prepares for future Phase III studies and potential commercialization. The exclusive agreement ensures that Psyence Biomed will use Optimi’s psilocybin extract for its drug development and FDA registration efforts.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
